Smithers Avanza Adds Quanterix’ Simoa HD-1 Analyzer

GAITHERSBURG, MD, USA – Smithers Avanza has added the Simoa HD-1 Analyzer to its Bioanalytical Laboratory. With this addition, the company will augment its existing stable of lab instrumentation, allowing for increased efficiency and capacity for testing related to the development and validation of immunoassays that are used during the development of biologics. The Simoa HD-1 Analyzer is a fully-automated instrument for running immunoassays using Quanterix’ proprietary single molecule array, or Simoa, platform.
 
“We are continuously looking at how we can provide greater value to our clients,” said Ira DuBey, Executive Vice President, Smithers Avanza Bioanalytical Services. “Adding technology such as the Simoa HD-1 with its very high sensitivity helps us to deliver the testing results our clients require as they develop the new generation of medicines.” 
 
Simoa is a digital form of ELISA, trapping and sealing individual immunocomplexes on paramagnetic beads in thousands of femtoliter sized wells in arrays found on the Simoa Discs. Simoa enables development of methods that may provide earlier disease detection.
  
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.
 
 

Back to News